Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 2:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 143 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Oral bacterial study Clear all
Completed Phase 3 Interventional Results available

Study to Compare Lefamulin to Moxifloxacin (With or Without Linezolid) for the Treatment of Adults With Pneumonia

NCT02559310
View directory record Official record
Conditions
Community Acquired Pneumonia
Interventions
lefamulin, Moxifloxacin, Linezolid
Drug
Lead sponsor
Nabriva Therapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
551 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
7
States / cities
Hazard, Kentucky • Shreveport, Louisiana • Minneapolis, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2019 · Synced Sep 6, 2026, 2:37 PM EDT
Terminated Phase 2 Interventional

Efficacy and Safety Study of JNJ-32729463 Compared With Moxifloxacin for the Treatment of Subjects Requiring Hospitalization for Community-Acquired Bacterial Pneumonia

NCT01198626
View directory record Official record
Conditions
Community-Acquired Bacterial Pneumonia (CABP)
Interventions
JNJ-32729463, moxifloxacin, JNJ-32729463 (Open-Label)
Drug
Lead sponsor
Furiex Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 85 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
13
States / cities
Mobile, Alabama • Sylmar, California • Orlando, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2011 · Synced Sep 6, 2026, 2:37 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Oral Bacterial Extract for the Prevention of Wheezing Lower Respiratory Tract Illness

NCT02148796
View directory record Official record
Conditions
Asthma, Wheezing
Interventions
Broncho-Vaxom (BV), Placebo
Drug · Other
Lead sponsor
University of Arizona
Other
Eligibility
6 Months to 18 Months
Enrollment
822 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2026
U.S. locations
11
States / cities
Phoenix, Arizona • Tucson, Arizona • Oakland, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 6, 2026, 2:37 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study of the Composition of Dental Plaque

NCT00001726
View directory record Official record
Conditions
Dental Caries, Dental Plaque, Periodontal Disease
Interventions
Not listed
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 6, 2026, 2:37 PM EDT
Terminated Phase 3 Interventional

Phase III Randomized Study of SYNSORB Pk in Children With E. Coli-Associated Hemolytic Uremic Syndrome

NCT00004465
View directory record Official record
Conditions
Hemolytic Uremic Syndrome
Interventions
SYNSORB Pk, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
6 Months to 18 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
26
States / cities
Denver, Colorado • Wilmington, Delaware • Atlanta, Georgia + 23 more
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Sep 6, 2026, 2:37 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection

NCT01259726
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
VP20621, Placebo
Biological · Other
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
42
States / cities
Modesto, California • Palm Desert, California • Sacramento, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Sep 6, 2026, 2:37 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Bacterial Overgrowth Associated With Chronic Multisymptom Illness Complex

NCT00956150
View directory record Official record
Conditions
Gulf War Syndrome
Interventions
Lactulose Breath Test, Rifaximin, Placebo
Procedure · Drug
Lead sponsor
Henry C. Lin, MD
Federal
Eligibility
21 Years and older
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Apr 30, 2013 · Synced Sep 6, 2026, 2:37 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants

NCT02096263
View directory record Official record
Conditions
Poliomyelitis, Diphtheria, Haemophilus Influenzae Type b, Tetanus, Acellular Pertussis, Hepatitis B
Interventions
Infanrix hexa, Pediarix, ActHIB, Pentacel, Engerix-B, Infanrix, Hiberix, Prevnar13, Rotarix
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 12 Weeks
Enrollment
585 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
43
States / cities
Tucson, Arizona • Fayetteville, Arkansas • Anaheim, California + 38 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Sep 6, 2026, 2:37 PM EDT
Completed Phase 3 Interventional Results available

A Study of Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator in Participants From Birth to Less Than 12 Years of Age With Acute Bacterial Skin and Skin Structure Infections (MK-1986-018)

NCT03176134
View directory record Official record
Conditions
Acute Bacterial Skin and Skin Structure Infections
Interventions
Tedizolid phosphate, Comparator
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
1 Day to 11 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
8
States / cities
San Diego, California • Chicago, Illinois • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Sep 6, 2026, 2:37 PM EDT
Completed Phase 3 Interventional

Oral Sodium Fusidate (CEM-102) Versus Oral Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections

NCT02570490
View directory record Official record
Conditions
Acute Bacterial Skin and Skin Structure Infections
Interventions
sodium fusidate, linezolid
Drug
Lead sponsor
Arrevus Inc.
Industry
Eligibility
12 Years and older
Enrollment
716 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
60
States / cities
Anaheim, California • Bakersfield, California • Buena Park, California + 46 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2019 · Synced Sep 6, 2026, 2:37 PM EDT
Completed Phase 1 Interventional Results available

Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention

NCT03817125
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Placebo for antibiotic, Vancomycin pretreatment, Nivolumab, Matching Placebo for SER-401, SER-401
Drug
Lead sponsor
Parker Institute for Cancer Immunotherapy
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
7
States / cities
Los Angeles, California • Boston, Massachusetts • New Brunswick, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2024 · Synced Sep 6, 2026, 2:37 PM EDT
Completed Phase 2 Interventional Results available

A Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GSK2140944 in the Treatment of Uncomplicated Urogenital Gonorrhea Caused by Neisseria Gonorrhoeae

NCT02294682
View directory record Official record
Conditions
Gonorrhea
Interventions
GSK2140944
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
12
States / cities
Fountain Valley, California • Los Angeles, California • Palm Springs, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 22, 2017 · Synced Sep 6, 2026, 2:37 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Pinpoint Trial: Prebiotics IN Peanut Oral ImmunoTherapy

NCT05138757
View directory record Official record
Conditions
Peanut Allergy
Interventions
Prebiotic, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
4 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
Chicago, Illinois • Hyde Park, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Sep 6, 2026, 2:37 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Safety, and Efficacy Study of ShigETEC, a Live, Attenuated, Oral Combination Vaccine to Prevent Shigella and ETEC Disease Delivered to Healthy Adults Ages 18 to 50 Years Old

NCT07049159
View directory record Official record
Conditions
Shigella
Interventions
ShigETEC vaccine, Placebo, Challenge: Shigella flexneri 2457T at a dose of 1.5x10^3 CFU
Biological · Other
Lead sponsor
Eveliqure Biotechnologies GmbH
Industry
Eligibility
18 Years to 50 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 7, 2025 · Synced Sep 6, 2026, 2:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Efficacy and Safety of 12-weeks Supplementation of Eubacterium Hallii on Insulin Sensitivity and Glycaemic Control

NCT04529473
View directory record Official record
Conditions
Pre Diabetes, Impaired Glucose Tolerance, Insulin Sensitivity, Insulin Resistance, Glucose Metabolism Disorders, Metabolic Syndrome
Interventions
Eubacterium hallii, Placebo
Dietary Supplement · Other
Lead sponsor
Atlantia Food Clinical Trials
Industry
Eligibility
21 Years to 69 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Sep 6, 2026, 2:37 PM EDT
Completed Phase 2 Interventional Results available

Oral Lenalidomide and Intravesical BCG for Therapy of Bladder Cancer

NCT01373294
View directory record Official record
Conditions
Bladder Cancer
Interventions
Bacille Calmette-Guerrin (BCG), Lenalidomide
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 5, 2019 · Synced Sep 6, 2026, 2:37 PM EDT
Withdrawn No phase listed Observational

Analysis of Oral Mucositis in Patient's Undergoing Melphalan Conditioning and Autologous Stem Cell Transplant

NCT02589860
View directory record Official record
Conditions
Mucositis, Multiple Myeloma, Amyloidosis, Oral Mucositis
Interventions
Melphalan kinetic study, Oral bacterial study, Gene expression study
Other · Genetic
Lead sponsor
Sherif S. Farag
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 9, 2022 · Synced Sep 6, 2026, 2:37 PM EDT
Completed Phase 3 Interventional Results available

Study to Compare Lefamulin to Moxifloxacin for the Treatment of Adults With Pneumonia

NCT02813694
View directory record Official record
Conditions
Community Acquired Pneumonia
Interventions
lefamulin, Moxifloxacin
Drug
Lead sponsor
Nabriva Therapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
738 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
25
States / cities
Beverly Hills, California • Fresno, California • Northridge, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2019 · Synced Sep 6, 2026, 2:37 PM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary Incontinence

NCT01767519
View directory record Official record
Conditions
Overactive Bladder, Urinary Incontinence
Interventions
BOTOX®, solifenacin, Botox placebo (normal saline), solifenacin placebo
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Apr 22, 2019 · Synced Sep 6, 2026, 2:37 PM EDT
Completed Phase 2Phase 3 Interventional

Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Community Acquired Bacterial Pneumonia (CABP)

NCT01530763
View directory record Official record
Conditions
Infections, Community Acquired Pneumonia
Interventions
Ceftaroline fosamil, Ceftriaxone, amoxicillin clavulanate
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
2 Months to 18 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
13
States / cities
Long Beach, California • Oakland, California • Orange, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2015 · Synced Sep 6, 2026, 2:37 PM EDT
Terminated Not applicable Interventional Results available

Diabetic Foot Infection Antibiotic Study

NCT01539811
View directory record Official record
Conditions
Diabetic Foot Infections
Interventions
Surgical incision and drainage of diabetic foot infection, Short course antibiotics, Long course antibiotics
Procedure · Drug
Lead sponsor
Prisma Health-Upstate
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Sep 6, 2026, 2:37 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Botanical Blend on the Gut Microbiome and Gut-Skin-Axis in Small Intestinal Bacterial Overgrowth (SIBO)

NCT04867512
View directory record Official record
Conditions
Small Intestinal Bacterial Overgrowth (SIBO)
Interventions
Liquid Tincture, GI Detox, Olivirex
Dietary Supplement
Lead sponsor
Integrative Skin Science and Research
Industry
Eligibility
18 Years to 60 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Sep 6, 2026, 2:37 PM EDT
Completed Phase 2 Interventional Results available

Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections

NCT02045797
View directory record Official record
Conditions
Infections, Bacterial
Interventions
GSK2140944 Lyophile, GSK2140944 Capsules
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
30
States / cities
Phoenix, Arizona • Anaheim, California • Chula Vista, California + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2017 · Synced Sep 6, 2026, 2:37 PM EDT
Completed Not applicable Interventional

Randomized Trial to Assess PO Versus IV Antibiotics

NCT01714596
View directory record Official record
Conditions
Wound Infection
Interventions
PO versus IV antibiotics Route of administration evaluation
Other
Lead sponsor
Major Extremity Trauma Research Consortium
Other
Eligibility
18 Years to 84 Years
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
24
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2021 · Synced Sep 6, 2026, 2:37 PM EDT